Filing Flows › Harvard Bioscience (HBIO) › Q2 2025
Harvard Bioscience (HBIO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 11, 2025
Harvard Bioscience (HBIO) reported revenue of $20.4M for the second quarter 2025 (Q2 2025), -11% from a year earlier and -6% from the quarter before. Operating margin was -4.0%, net loss $2.3M (11.2% of revenue).
Harvard Bioscience, Q2 2025: revenue $20.4M (-12% year over year), operating margin -4.0%, net loss $2.3M, operating cash flow $2.8M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.4M | -6% | -11% |
| Operating profit | −$819K | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | $2.8M | -8% | — |
| Free cash flow | $2.7M | +8% | — |
What changed
Revenue was $20.4M in Q2 2025, down 11% year over year and down 6% from the previous quarter. Instruments, Equipment, Software, and Accessories was the largest line at 89% of revenue. Instruments, Equipment, Software, and Accessories lost $3.1M year over year (down 15%), 118% of the total change.
Gross margin was 56.4%, down 0.8 points from a year earlier. Operating costs exceeded revenue by $819K, an operating margin of -4.0%. Operating expenses fell 19% while revenue fell 11%. The quarter ended with a net loss of $2.3M, narrower than the previous quarter's $50.3M loss. Net interest and other expense of $1.4M was the main reason.
Operating cash flow was $2.8M. Non-cash charges added back $1.6M of depreciation and amortization and $472K of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $89K left free cash flow of $2.7M.
Questions
What was Harvard Bioscience's revenue in the second quarter 2025?
Harvard Bioscience (HBIO) reported revenue of $20.4M for the second quarter 2025 (Q2 2025), -11% from a year earlier and -6% from the quarter before.
Was Harvard Bioscience profitable in the second quarter 2025?
Operating loss was $819K (-4.0% of revenue) and net loss $2.3M.
Source: Harvard Bioscience 10-Q on SEC EDGAR.